Nektar Q1 2024 Earnings Report
Key Takeaways
Nektar Therapeutics reported first quarter 2024 financial results with revenue of $21.6 million and a net loss of $36.8 million, or $0.19 loss per share. Cash and investments were $326.0 million at the end of the quarter, expected to support operations into the third quarter of 2026. The company is advancing its immunology and inflammation pipeline, with Phase 2b studies for REZPEG on track.
Cash and investments in marketable securities were $326.0 million as of March 31, 2024.
Revenue for the first quarter of 2024 was $21.6 million, consistent with the first quarter of 2023.
Net loss for the first quarter of 2024 was $36.8 million, or $0.19 loss per share.
Advancing REZPEG in Phase 2b studies for atopic dermatitis and alopecia areata, with topline data expected in the first half of 2025.
Nektar
Nektar
Forward Guidance
Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026.